Editas Medicine, Inc.

The company is a biotechnology firm that develops genomic medicines utilizing CRISPR-based gene editing technology, including Cas9 and Cas12a systems. Its core scientific approach focuses on in vivo functional upregulation, which edits non-coding regulatory DNA sequences to increase normal gene and protein expression. The firm's lead experimental product candidate is EDIT-401, designed to treat hyperlipidemia and heterozygous familial hypercholesterolemia by targeting the low-density lipoprotein receptor gene. The organization also researches in vivo treatments for hemoglobinopathies such as sickle cell disease and transfusion-dependent beta thalassemia, alongside a lipid nanoparticle delivery platform for liver and extrahepatic tissues. It serves patients with genetic conditions and collaborates with biopharmaceutical partners by out-licensing its intellectual property for cancer and autoimmune disease therapies.

The text does not identify the company's headquarters location, employee figures, or physical facility locations. Its stated operational scope includes a partnership portfolio of fourteen research programs with Bristol Myers Squibb and global licensing arrangements with pharmaceutical collaborators.

Summary of the business section of Editas Medicine's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 1, 2026, we had 87 full-time employees, including 26 employees with M.D.”